The Share

The Diamyd Medical share is traded on Nasdaq First North (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North

Nasdaq First North is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Annual Report

  November 9, 2017
  Annual Report, November 9, 2017

Dear Shareholders and readers

In last year’s CEO comments, I highlighted the potential of our project portfolio and our focus on refining these values in the best possible way through efficient resource prioritization. I can now look back with pride on what we have achieved during the year and what it will mean for the new fiscal year.

Over the past year, we have received both preliminary and final results from four investigator-initiated clinical trials with the diabetes vaccine Diamyd®. A high safety...

DIAGNODE-2 defines large parts of the fiscal year with a major focus on achieving efficient patient recruitment.
Ulf Hannelius, President and CEO

Event Calendar

 Dates for financial information and other events
December 11, 2017
Feminvest / Nordnet event
Event focusing on the pharmaceutical industry. Event registration.

Financial Calendar

 January 24, 2018
Quarterly Report 1 2016/2017
 March 28, 2018
Quarterly Report 2 2017/2018
 June 27, 2018
Quarterly Report 3 2017/2018
 October 10, 2018
Financial statement 2017/2018
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of September 29, 2017

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 130 186 6 110 867 14.63 36.31
Avanza Pension 7 034 437 12.49 9.32
Lindkvist, Bertil 6 160 000 10.93 8.16
Nordnet Pensionsförsäkring AB 2 165 206 3.84 2.87
Swedbank Försäkring 816 927 1.45 1.08
Relbo AB 396 292 0.70 0.52
Schèle, Sven 358 670 0.64 0.48
Arandi Development AB 350 000 0.62 0.46
Försäkrings AB Skandia 350 874 0.62 0.46
Bohlin, Lennart 345 571 0.61 0.46
Remaining shareholders 30 117 895 53.5 39.9
Total 2 130 186 54 206 739 100.0 100.0